Revolution Medicines (RVMD) investor relations material

Introduction and purpose

• FDA approved RASONQUE (daraxonrasib) oral tablets for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

• RASONQUE is the first targeted cancer medicine from a new class of RAS (ON) multi-selective and mutant-selective inhibitors, marking the first proof point for a RAS (ON) inhibitor strategy targeting a critical oncogenic driver in mPDAC.

Details of approval or decision

• Approval is based on the global Phase 3 RASolute 302 trial, which compared RASONQUE to standard chemotherapy.

• RASONQUE is available as 100 mg and 150 mg oral tablets, with a recommended dose of 300 mg once daily, and is available immediately in the U.S. as an oral, once-daily therapy.

• The indication is not restricted by tumor RAS mutation status and does not require a companion diagnostic.

• Full U.S. commercial launch is underway, with operational supply, distribution, and patient services.

Impact on industry and stakeholders

• RASONQUE is positioned to become the new standard of care for eligible metastatic pancreatic cancer patients, addressing a landscape unchanged for decades.

• Commercialization, manufacturing, and patient support infrastructure are fully operational for immediate launch, including the (ON) Path program for coverage navigation, financial and adherence support, and educational resources.

• The company is preparing for international expansion, with regulatory review underway in Europe and Japan, and EMA granting orphan medicinal product designation and high-priority status.

• Patient advocacy groups and clinical leaders highlight the potential for improved quality of life and survival.